This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Digirad Signs Exclusive International Distribution Agreement With Dilon Diagnostics

SUWANEE, Ga. and NEWPORT NEWS, Va., Aug. 22, 2013 /PRNewswire/ -- Digirad Corporation (NASDAQ: DRAD),  the leader in solid-state diagnostic imaging technology and services, and Dilon Diagnostics, the world leader in molecular breast imaging, today announced that they have signed an exclusive international distribution agreement for Dilon to distribute Digirad's lines of nuclear imaging cameras including the ergo™, a large field-of-view general purpose imaging system, the Cardius® x.act, a triple-head cardiac dedicated SPECT imaging system with VCT Attenuation Correction, and the Cardius® XPO dedicated cardiac SPECT imaging systems line.  The agreement covers distribution of Digirad products to most countries outside the United States.  The signing of this agreement furthers the relationship that Digirad and Dilon have been building since the two companies signed a technology development agreement in mid-2010.

(Logo:  http://photos.prnewswire.com/prnh/20130501/PH05456LOGO )

Digirad President and CEO Matthew G. Molchan said, "We are very pleased with this enhanced relationship with Dilon and the opportunity to further expand our product reach beyond the United States.  We continue to believe that our nuclear imaging cameras, with their solid-state design and technology, are well suited to meet the needs of the international market and we are very excited to partner with Dilon to distribute our cameras around the world.  We believe our products will be an excellent complement to the already extensive Dilon product line up."   

Dilon Diagnostics Chairman and CEO Robert G. Moussa said, "We are extremely pleased to expand our already successful partnership with Digirad and are excited to broaden our offering of nuclear imaging products in the international marketplace.  With the addition of the Digirad cameras to the existing Dilon product portfolio, we now have the ability to offer a full spectrum of diagnostic imaging solutions to our international customers and to afford the excellent range of Digirad's nuclear imaging products access to our broad international network of customers."

About Dilon DiagnosticsDilon Diagnostics, a brand of Dilon Technologies, Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/BSGI. MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon's GammaLoc® System is the only localization device on the market to enable molecular-guided breast biopsy. Many leading medical centers around the country are now offering MBI to their patients, including: Beth Israel and Cornell University Medical Centers in New York; Kaiser Permanente of Sacramento, CA and The George Washington University, Washington D.C. For more information on Dilon Diagnostics please visit www.dilon.com.

About Digirad CorporationDigirad is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.

Media Contact: Pjerin LuliDilon Technologies, Inc.757-269-4910 x 321 pluli@dilon.com

SOURCE Dilon Technologies, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs